Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from MicroPort CardioFlow Medtech Corp. ( (HK:2160) ) is now available.
MicroPort CardioFlow Medtech reported 2025 revenue of USD57.0 million, up 12.6% excluding foreign exchange effects, driven by the consolidation of MicroPort CRM and a 255% surge in overseas structural heart disease sales, though gross margin slipped to 65.0% amid price pressure in China. The group’s net loss widened to USD18.8 million from USD7.5 million as the newly consolidated CRM business weighed on profitability and prior-year investment gains did not recur, even as the completed merger with MicroPort CRM broadened its product portfolio, reduced reliance on a single segment, and repositioned the company as a more resilient, globally oriented cardiac device platform.
The most recent analyst rating on (HK:2160) stock is a Sell with a HK$0.74 price target. To see the full list of analyst forecasts on MicroPort CardioFlow Medtech Corp. stock, see the HK:2160 Stock Forecast page.
More about MicroPort CardioFlow Medtech Corp.
MicroPort CardioFlow Medtech Corp. is a Cayman Islands-incorporated medical device company focused on interventional treatment of structural heart diseases and cardiac rhythm management. By integrating high-end interventional devices such as VitaFlow Liberty and Alwide Plus with monitoring and data analytics capabilities from its CRM business, the company is evolving into a diversified global device solutions platform targeting the full spectrum of heart failure care.
Average Trading Volume: 1,987,675
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$4.05B
See more data about 2160 stock on TipRanks’ Stock Analysis page.